The AMPLY platform connects the digital biological biome to high volume peptide and protein extraction technology to unlock a new frontier in drug discovery. The AMPLY discovery cycle for novel compounds is rapid, effective and scaleable.
AMPLYfolio AI can process genomic, transcriptomic, meta-transcriptomic, metagenomic or synthetic data.
Data & Analytics
AMPLYfolio AI uses custom data-scanning techniques to locate regions of interest in digital biological data that other tools miss.
AMPLY uses black-box unpublished machine learning and bioinformatic methodologies to highlight novel compounds using a complex web of thousands of metadata tags.
AMPLY uses approaches leveraged from predictive marketing and the financial services industry and creates a "stock picking" dashboard view of the data it processes. This allows a user-driven selection of novel compounds
AMPLY uniquely connects the digital discovery technology to high throughput peptide synthesis and protein extraction techniques.
Essentially a 3D printing process for biological compounds.
Once compounds are printed the AMPLY pipeline includes a full lab validation of the kill-efficiency of compounds against target diseases. Additional testing, such as toxicity, anti-biofilm, biochemical handling criteria and resistance studies can be performed as desired.